PUK10 - Estimating The Economic Benefit Of Treatment With Alpha-Blocker Plus Antimuscarinic As A Fixed-Dose Combination (FDC) Tablet Versus Concomitant Combination Therapy (CCT) In Men With Lower Urinary Tract Symptoms (Luts) Associated With Benign Prostatic Hyperplasia (BPH)

MLA

Bowditch, S., et al. “PUK10 - Estimating The Economic Benefit Of Treatment With Alpha-Blocker Plus Antimuscarinic As A Fixed-Dose Combination (FDC) Tablet Versus Concomitant Combination Therapy (CCT) In Men With Lower Urinary Tract Symptoms (Luts) Associated With Benign Prostatic Hyperplasia (BPH).” Value in Health, vol. 20, no. 9, Oct. 2017, pp. A489–90. EBSCOhost, https://doi.org/10.1016/j.jval.2017.08.515.

APA

Bowditch, S., McCrea, C., Arbe, E., & Nazir, J. (2017). PUK10 - Estimating The Economic Benefit Of Treatment With Alpha-Blocker Plus Antimuscarinic As A Fixed-Dose Combination (FDC) Tablet Versus Concomitant Combination Therapy (CCT) In Men With Lower Urinary Tract Symptoms (Luts) Associated With Benign Prostatic Hyperplasia (BPH). Value in Health, 20(9), A489–A490. https://doi.org/10.1016/j.jval.2017.08.515

Chicago

Bowditch, S, C McCrea, E Arbe, and J Nazir. 2017. “PUK10 - Estimating The Economic Benefit Of Treatment With Alpha-Blocker Plus Antimuscarinic As A Fixed-Dose Combination (FDC) Tablet Versus Concomitant Combination Therapy (CCT) In Men With Lower Urinary Tract Symptoms (Luts) Associated With Benign Prostatic Hyperplasia (BPH).” Value in Health 20 (9): A489–90. doi:10.1016/j.jval.2017.08.515.